

IncrediBlock Advance Free

Description	IncrediBlock Advance Free is used with immunolabeling techniques for the reduction of nonspecific background staining, and simultaneously reducing the handling of animal serums in the laboratory. The need to match species with the secondary antibody is eliminated due to the lack of normal serum in this product. IncrediBlock Advance has been shown to be effective for immunohistochemical, ELISA, blot and in-situ techniques. It requires no mixing or diluting. pH: 7.4±0.1
Uses	Immunochemical procedures
Limitations	Do not use past expiration date.
Storage	Store IncrediBlock Advance Free at 2-8°C. Product is stable for 18 months from date of manufacture.
Procedure (Immunohistochemical)	<ol style="list-style-type: none">1. Incubate tissue section for 5 minutes at either room temperature or 37° C prior to application of the primary antibody. After incubation, rinse once in buffer <p><i>Note: Do not incubate tissue sections in excess of 10 minutes or a reduction in desired staining may occur.</i></p> <ol style="list-style-type: none">2. For bulk staining, pour IncrediBlock Advance Free in a covered staining tray and dip slides for 5 minutes. Replace with fresh IncrediBlock Advance after 5-10 uses. This step can be performed at the time of deparaffinization is desired. <p><i>For antibodies with particularly high background staining, dilute IncrediBlock Advance Free in PBS (1:5-10) and use as a wash buffer in addition to the blocking step.</i></p>
Procedure (ELISA)	<ol style="list-style-type: none">1. Incubate microtiter well for 2-10 minutes prior to addition of sample.2. Rinse, and continue procedure. (Note: do not incubate in excess of 10 minutes).
Procedure (Chemiluminescent Blotting)	IncrediBlock Advance Free is effective for this technique with incubation times of one hour at room temperature or when used with overnight incubations at 2-8° centigrade.
Precautions	Do not pipette reagent by mouth. Avoid contact with skin and eyes. Wash after use. Observe all federal, state and local environmental regulations regarding disposal.
References	<ol style="list-style-type: none">1. Buttini M., Yu G.Q., Shockley K., Huang Y., et al. Modulation of

- Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform, Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation. *The Journal of Neuroscience*, Vol. 22, No. 24, pp 10539- 10548, December 15, 2002.
2. Evans C.F., Horwitz M.S., Hobbs M.V., Oldstone M. Viral Infection of Transgenic Mice Expressing a Viral Protein in Oligodendrocytes Leads to Chronic Central Nervous System Autoimmune Disease. *Journal of Experimental Medicine*, Vol. 184 pp 2371-2384, December 1996.
 3. Goleva E., Kisich K.O., Leung D.Y.M. A Role for STAT5 in the Pathogenesis of IL-2-Induced Glucocorticoid Resistance. *The Journal of Immunology*, Vol. 169, pp 5934-5940, 2000.
 4. Lee E.H., Seomun Y., Hwang K.H., Kim J.E., Kim I.S., Kim J.H., Joo C.K. Overexpression of the Transforming Growth Factor- β -Inducible Gene β ig-h3 in Anterior Polar Cataracts. *Investigational Ophthalmology & Visual Science*, Vol. 41, No. 7, pp 1840-1845, June 2000.
 5. Lemaitre V., O'Byrne T.K., Borczuk A.C., et al. ApoE Knockout Mice Expressing Human Matrix Metalloproteinase-1 in Macrophages have less Advanced Atherosclerosis. *The Journal of Clinical Investigation*, Vol. 107, No. 10, pp 1227-1234, May 2001.
 6. Matsubara S., Wada Y., Gardner T.A., et al. A Conditional Replication-competent Adenoviral Vector, Ad- OC- E1a, to Cotarget Prostate Cancer and Bone Stroma in an Experimental Model of Androgen- independent Prostate Cancer Bone Metastasis. *Cancer Research*, Vol. 61, pp 6012-6019, August 15, 2001
 7. Pauley R.J., Santner S.J., Tait L.R., Bright R.K., Stanten R.J. Regulated CYP19 Aromatase Transcription in Breast Stromal Fibroblasts. *The Journal of Clinical Endocrinology & Metabolism*, Vol. 85, No. 2, pp 837-846, 2000.
 8. Nemeth J.A., Yousif R., Herzog M., et al. Matrix Metalloproteinase Activity, Bone Matrix Turnover, and Tumor Cell Proliferation in Prostate Cancer Bone Metastasis. *Journal of the National Cancer Institute*, Vol. 94, No. 1, pp 17-25, January 2, 2002.
 9. Nemeth J.A., Harb J.F., Barroso U., et al. Severe Combined Immunodeficient-hu Model of Human Prostate Cancer Metastasis to Human Bone. *Cancer Research*, Vol. 59, pp 1987-1993, April 15, 1999.
 10. Slominski A., Rologg B., Curry J., et al. The Skin Produces Urocortin. *The Journal of Clinical Endocrinology & Metabolism*, Vol. 85, No. 2, pp 815-823, 2000.